Company Description

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.

The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis.

The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Ardelyx, Inc.

Country	United States
Founded	2007
IPO Date	Jun 19, 2014
Industry	Biotechnology
Sector	Healthcare
Employees	395
CEO	Michael Raab

Contact Details

Address: 400 Fifth Avenue, Suite 210 Waltham, Massachusetts 02451 United States
Phone	510 745 1700
Website	ardelyx.com

Stock Details

Ticker Symbol	ARDX
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001437402
CUSIP Number	039697107
ISIN Number	US0396971071
SIC Code	2834

Key Executives

Name	Position
Michael G. Raab	President, Chief Executive Officer and Director
Elizabeth A. Grammer Esq.	General Counsel
Dr. Laura A. Williams M.D., M.P.H.	Chief Patient Officer and Interim Chief Medical Officer
Mike Kelliher	Chief Business Officer
Sue Hohenleitner	Chief Financial Officer
Joseph Reilly	Senior Vice President of Finance and Principal Accounting Officer
Caitlin Lowie	Vice President of Corporate Communications and Investor Relations
James P. Brady	Chief Human Resources Officer
Eric Duane Foster	Chief Commercial Officer
Dr. John Bishop Ph.D.	Chief Technical Operations Officer

Latest SEC Filings

Date	Type	Title
Jan 8, 2026	144	Filing
Jan 8, 2026	8-K	Current Report
Dec 17, 2025	8-K	Current Report
Nov 24, 2025	144	Filing
Nov 20, 2025	144	Filing
Nov 20, 2025	144	Filing
Nov 20, 2025	144	Filing
Nov 20, 2025	144	Filing
Nov 20, 2025	144	Filing
Nov 20, 2025	144	Filing

View All SEC Filings